Chronic Spontaneous Urticaria: A Leading Driver Behind Impact Of Increasing Alcohol Consumption On The Chronic Spontaneous Urticaria Market Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Chronic Spontaneous Urticaria Industry Market Size Be by 2025?
There has been a robust growth in the chronic spontaneous urticaria market in the past few years. It is projected to escalate from $2.06 billion in 2024 to $2.23 billion in 2025, rising at a compound annual growth rate (CAGR) of 8.6%. The historical growth is attributed to advancements in diagnostic tools, increased awareness among healthcare providers, support and advocacy groups for patients, the pursuit of new therapeutics through ongoing studies and clinical trials, and an increase in healthcare spending.

What's the Long-Term Growth Forecast for the Chronic Spontaneous Urticaria Market Size Through 2029?
In the coming years, the market size of chronic spontaneous urticaria is anticipated to experience robust growth. The market is projected to reach a value of $3.08 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.4%. This growth within the forecasted period could be due to several factors including the rising count of diagnosed CSU cases, an increasingly large patient pool, improvements in healthcare infrastructure, supportive regulatory surroundings, the adoption of patient-oriented care models, and economic progress in emerging markets. The forecast period is also likely to witness major trends such as technological enhancements, progress in biological therapies, the rise of personalized medicine and digital health via telemedicine, utilization of high-end diagnostic instruments, application of artificial intelligence and machine learning, and an increase in drug approvals and launches.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

What Are the Key Growth Drivers Fueling the Chronic Spontaneous Urticaria Market Expansion?
The surge in alcohol intake is projected to fuel the expansion of the chronic spontaneous urticaria market. This increase in alcohol usage is due to a variety of factors such as societal expectations, stress, marketing strategies, cost-effectiveness, and easy accessibility. Consumption of alcohol may potentially worsen chronic spontaneous urticaria symptoms in certain individuals, resulting in increased outbreaks of hives and inflammation. For example, rehabs.UK, a UK-based addiction recovery support provider, reported in February 2024, that 55% of men and 41% of women consumed alcohol on a weekly basis. Further, 8% of men and 5% of women reported nearly daily alcohol consumption. Between 2021 and 2022, hospital admissions due solely to alcohol amounted to 342,795, equivalent to a rate of 626 admissions per 100,000 people. Consequently, the uptick in alcohol consumption is spurring growth in the chronic spontaneous urticaria market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

What Are the Key Trends Driving Chronic Spontaneous Urticaria Market Growth?
Leading corporations active in the chronic spontaneous urticaria market are focusing on the creation of advanced Briquilimab (JSP191), the next-generation solution, to boost the effectiveness of treatments and decrease the requirement for frequent doses. The next-gen Briquilimab (JSP191) is a monoclonal antibody specifically developed to target and eliminate certain immune cells, including those associated with CD47, a key factor in chronic spontaneous urticaria. For example, in November 2023, Jasper Therapeutics Inc., an American clinical-stage biotech company, revealed it had initiated its first patient treatment in a Phase 1b/2a clinical trial of Briquilimab for chronic spontaneous urticaria (CSU). The initiation of this trial denotes a significant move towards evaluating the safety and performance of Briquilimab, a cutting-edge monoclonal antibody targeting CD47, in treating this recurring medical condition involving hives and itching. The study's main objective is to determine the extent to which Briquilimab can ease the symptoms and enhance life quality for individuals affected by CSU.

How Is the Chronic Spontaneous Urticaria Market Segmented?
The chronic spontaneous urticaria market covered in this report is segmented -

1) By Treatment: Medication, Phototherapy, Other Treatments
2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administration
3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis
4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids (Oral and Topical)
2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy
3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy (for Stress-Related Triggers)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Which Companies Are Leading the Charge in Chronic Spontaneous Urticaria Market Innovation?
Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Which Regions Are Leading the Global Chronic Spontaneous Urticaria Market in Revenue?
North America was the largest region in the chronic spontaneous urticaria market in 2023. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16651

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.